Basilea Pharmaceutica AG Stock Xetra
Equities
PK5
CH0011432447
Biotechnology & Medical Research
Sales 2024 * | 182M 202M 188M 277M | Sales 2025 * | 198M 219M 204M 301M | Capitalization | 471M 521M 486M 716M |
---|---|---|---|---|---|
Net income 2024 * | 26M 28.76M 26.8M 39.51M | Net income 2025 * | 29M 32.08M 29.89M 44.07M | EV / Sales 2024 * | 2.9 x |
Net Debt 2024 * | 56.76M 62.79M 58.51M 86.25M | Net Debt 2025 * | 12.51M 13.84M 12.89M 19.01M | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
16.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
1st Jan change | Capi. | |
---|---|---|
+16.05% | 45.51B | |
-9.69% | 38.52B | |
+38.08% | 38.13B | |
+27.90% | 30.74B | |
-8.64% | 26.03B | |
+11.67% | 25.92B | |
+45.08% | 14.13B | |
+33.59% | 12.73B | |
-7.81% | 11.29B |